In the ATN framework, AD is defined by the simultaneous deposition of two biomarkers, β-amyloid (A) and pathological tau (T), followed by neuronal damage or neurodegeneration (N) (Jack et al., 2018). The gene discussed is MAPT; the disease is Alzheimer disease.